Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2026)
Autolus Therapeutics' (AUTL) quarterly Cost of Revenue came in at $25.3 million in Q4 2025, up 122.45% YoY from $11.4 million in Q4 2024, and down 11.57% on a QoQ basis from $28.6 million in Q3 2025.
Powered by 
Analysis
Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 2 years of Cost of Revenue data on file, last reported at $25.3 million in Q4 2025.
- Quarterly Cost of Revenue rose 122.45% year-over-year to $25.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96.4 million (up 746.31% YoY) and the FY2025 annual result came in at $96.4 million, up 746.31% from the prior year.
- Cost of Revenue retreated to $25.3 million in Q4 2025, from $28.6 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $28.6 million in Q3 2025 to a low of $11.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Autolus Therapeutics | 594.86 Mn | 393.23 Mn | 25.22 Mn | 20.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.47 Mn |
| Dec 31, 2025 | 25.33 Mn |
| Sep 30, 2025 | 28.64 Mn |
| Jun 30, 2025 | 24.45 Mn |
| Mar 31, 2025 | 17.95 Mn |
| Dec 31, 2024 | 11.39 Mn |